What does Relst Pharma do?

Relst Pharma is a pharmacy in Kampenhout. Private Limited, started on 9 July 1990, 1 establishment.

What is the address of Relst Pharma?

The registered office of Relst Pharma is located at Haachtsesteenweg 512, 1910 Kampenhout.

Is Relst Pharma still active?

Yes. According to the CBE (30 October 2026) Relst Pharma is active, legal situation “Normale toestand”, started on 9 July 1990.

Is Relst Pharma registered on Peppol?

Yes, Relst Pharma is registered on the Peppol network with ID 0208:0441339112.

What is the enterprise number of Relst Pharma?

The enterprise number of Relst Pharma is BE0441339112.

When was Relst Pharma founded?

Relst Pharma was founded on 9 July 1990.

Who are the directors of Relst Pharma?

According to the 2025 annual accounts, the directors of Relst Pharma are: Giura Pharma, Pharma Deprée BV BV.

Is Relst Pharma a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 9 July 1990; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did Relst Pharma make in 2025?

Relst Pharma posted a profit after taxes of € 104,934 in financial year 2025.

What is the revenue of Relst Pharma?

As a small company, Relst Pharma is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 168,737.

How many employees does Relst Pharma have?

According to the 2025 annual accounts, Relst Pharma has 0.3 full-time equivalents (FTE).

Does Relst Pharma have a website?

Yes, Relst Pharma has a website at relstpharma.be.

Relst Pharma (Private Limited) - Kampenhout

Dossier Relst Pharma, printed on 30 October 2026 from databakkes.be/en/0441339112/relst-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

Relst Pharma from Kampenhout, company number BE0441339112, closed financial year 2025 with a result of € 104,934 after tax. For that financial year Relst Pharma recorded a gross margin of € 168,737 and equity of € 473,342. Compared with financial year 2024, the result moved from € 167,487 to € 104,934. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 9, 2026.

What it is worth Growing

€ 473,342

▲ 28% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 104,934

▼ 37% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 104,325

▲ 57% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 467,142.

People and assets in 2025

Full-time equivalents

0.3

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 15,745

▲ € 14,660 vs 2024

Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 2,274

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 3 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 35,222

▼ 26% vs 2024

€ 12,632 is repaid this year. At this pace the long-term loan is gone in ≈ 3 years.

Owed to suppliers

€ 202,590

▲ 57% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 2,930

▲ € 2,451 vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 147,865 Gross margin 2022: € 147,865 First fiscal year in the series	€ 136,139 Gross margin 2023: € 136,139 ▼ 8% vs 2022 (€ 147,865) Unfavourable step	€ 194,246 Gross margin 2024: € 194,246 ▲ 43% vs 2023 (€ 136,139) Favourable step	€ 168,737 Gross margin 2025: € 168,737 ▼ 13% vs 2024 (€ 194,246) Unfavourable step	▼ 13%
Profit after taxes	€ 132,146 Profit after taxes 2022: € 132,146 First fiscal year in the series	€ 116,105 Profit after taxes 2023: € 116,105 ▼ 12% vs 2022 (€ 132,146) Unfavourable step	€ 167,487 Profit after taxes 2024: € 167,487 ▲ 44% vs 2023 (€ 116,105) Favourable step	€ 104,934 Profit after taxes 2025: € 104,934 ▼ 37% vs 2024 (€ 167,487) Unfavourable step	▼ 37%
Equity	€ 307,817 Equity 2022: € 307,817 First fiscal year in the series	€ 323,922 Equity 2023: € 323,922 ▲ 5% vs 2022 (€ 307,817) Favourable step	€ 368,408 Equity 2024: € 368,408 ▲ 14% vs 2023 (€ 323,922) Favourable step	€ 473,342 Equity 2025: € 473,342 ▲ 28% vs 2024 (€ 368,408) Favourable step	▲ 28%
Total debts	€ 239,803 Total debts 2022: € 239,803 First fiscal year in the series	€ 362,897 Total debts 2023: € 362,897 ▲ 51% vs 2022 (€ 239,803) Unfavourable step	€ 300,510 Total debts 2024: € 300,510 ▼ 17% vs 2023 (€ 362,897) Favourable step	€ 241,200 Total debts 2025: € 241,200 ▼ 20% vs 2024 (€ 300,510) Favourable step	▼ 20%
Cash	€ 49,731 Cash 2022: € 49,731 First fiscal year in the series	€ 102,897 Cash 2023: € 102,897 ▲ 107% vs 2022 (€ 49,731) Favourable step	€ 66,308 Cash 2024: € 66,308 ▼ 36% vs 2023 (€ 102,897) Unfavourable step	€ 104,325 Cash 2025: € 104,325 ▲ 57% vs 2024 (€ 66,308) Favourable step	▲ 57%
Land & buildings	€ 225,000 Land & buildings 2022: € 225,000 First fiscal year in the series	€ 225,000 Land & buildings 2023: € 225,000 Unchanged (€ 225,000) Unchanged	€ 225,000 Land & buildings 2024: € 225,000 Unchanged (€ 225,000) Unchanged	€ 225,000 Land & buildings 2025: € 225,000 Unchanged (€ 225,000) Unchanged
Retained profit	€ 301,617 Retained profit 2022: € 301,617 First fiscal year in the series	€ 317,722 Retained profit 2023: € 317,722 ▲ 5% vs 2022 (€ 301,617) Favourable step	€ 362,208 Retained profit 2024: € 362,208 ▲ 14% vs 2023 (€ 317,722) Favourable step	€ 467,142 Retained profit 2025: € 467,142 ▲ 29% vs 2024 (€ 362,208) Favourable step	▲ 29%
Dividend	€ 125,000 Dividend 2022: € 125,000 First fiscal year in the series	€ 100,000 Dividend 2023: € 100,000 ▼ 20% vs 2022 (€ 125,000) Unchanged	€ 123,000 Dividend 2024: € 123,000 ▲ 23% vs 2023 (€ 100,000) Unchanged	€ 0 Dividend 2025: € 0 ▼ 100% vs 2024 (€ 123,000) Unchanged	▼ 100%
Bank debt	€ 76,620 Bank debt 2022: € 76,620 First fiscal year in the series	€ 59,895 Bank debt 2023: € 59,895 ▼ 22% vs 2022 (€ 76,620) Favourable step	€ 47,656 Bank debt 2024: € 47,656 ▼ 20% vs 2023 (€ 59,895) Favourable step	€ 35,222 Bank debt 2025: € 35,222 ▼ 26% vs 2024 (€ 47,656) Favourable step	▼ 26%
Balance sheet total	€ 547,620 Balance sheet total 2022: € 547,620 First fiscal year in the series	€ 686,819 Balance sheet total 2023: € 686,819 ▲ 25% vs 2022 (€ 547,620) Unchanged	€ 668,918 Balance sheet total 2024: € 668,918 ▼ 3% vs 2023 (€ 686,819) Unchanged	€ 714,542 Balance sheet total 2025: € 714,542 ▲ 7% vs 2024 (€ 668,918) Unchanged	▲ 7%
Employees (FTE)	0 Employees (FTE) 2022: 0 First fiscal year in the series	0 Employees (FTE) 2023: 0 Unchanged (0) Unchanged	0 Employees (FTE) 2024: 0 Unchanged (0) Unchanged	0.3 Employees (FTE) 2025: 0.3 Unchanged (0) Unchanged

Key figures of Relst Pharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Relst Pharma?

What happened at Relst Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jun 9, 2026 New annual accounts for financial year 2025: profit of € 104,934 (▼ 37% vs 2024). Source: NBB ↗
2018 Giura Pharma became a director. NBB
2018 Pharma Deprée BV BV became a director. NBB
Sep 14, 1994 New establishment in Kampenhout. KBO
Jul 9, 1990 Start of the company according to the CBE. KBO

In short

From € 132,146 profit in 2022 to € 104,934 profit in 2025.

Paid € 58,459 in corporate taxes since 2022.

Best year ever: 2024, with € 167,487 profit.

Paid out € 348,000 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

Pharma Deprée 50%

Giura Pharma 50%

The stake of Pharma Deprée, Giura Pharma comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

Relst Pharma

Behind Relst Pharma are Giura Pharma and Pharma Deprée BV BV. The shares are held by Pharma Deprée (50%) and Giura Pharma (50%).

Directors

According to the 2025 annual accounts

Giura Pharma

Director · represented by Caroline Caenepeel

Also active at: APOTREM

since 2018

Pharma Deprée BV BV

Director · represented by Inne Deprée

Also active at: APOTREM

since 2018

Shareholders

Pharma Deprée

50%

Giura Pharma

50%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Haachtsesteenweg 512

1910 Kampenhout

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Website

HTTPS relstpharma.be

Canonical: https://www.relstpharma.be

Technologies

Advanced Custom FieldsLodashPWAReactWixlazysizes

Hosting & Email

Email provider

Microsoft 365

Hosting

WIX_COM, IL

Website info

HTTPS Ja

Languages NL

Features

Security

✓ HTTPS

✗ SPF

✗ DMARC

Network

✓ Load balancing

Details

Company number

0441.339.112

VAT number

BE 0441.339.112

Registered office

Haachtsesteenweg 512, 1910 Kampenhout

Names & denominations

Relst Pharma

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

9 July 1990

Peppol

Active · Active since 1 Mar 2024

Contact

relstpharma.be

Activities · NACE

Detailhandel in farmaceutische producten

Apothekers

View on CBE Public ↗ Annual accounts (NBB) ↗

Relst Pharma

Financials

What happened to Relst Pharma?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Website

Technologies

Hosting & Email

Website info

Features

Security

Network

Details

Frequently asked questions